Research Guide · Updated June 2026
Retatrutide vs Tirzepatide vs Semaglutide — Research Comparison
Three GLP-1-class compounds dominate metabolic peptide research right now. This is a strictly in-vitro / pharmacology-focused comparison — not dosing or human-use advice.
Receptor profile
Semaglutide: selective GLP-1 receptor agonist. The reference molecule in this class.
Tirzepatide: dual GIP / GLP-1 receptor agonist. Adds GIP-receptor activity on top of GLP-1.
Retatrutide: triple GLP-1 / GIP / glucagon receptor agonist. The newest of the three and the broadest receptor profile.
Why researchers compare them
In-vitro receptor binding assays, cyclic-AMP signalling studies and β-arrestin recruitment comparisons all sit naturally as a three-way panel. Comparative half-life modelling and pancreatic β-cell line secretion assays are common downstream experiments.
What to check before ordering
All three should ship at ≥99% HPLC purity, with batch-specific CoA available on request. Professor Peptide stocks Semaglutide, Tirzepatide and Retatrutide as UK-dispatched research peptides, all with CoA on request.
Frequently Asked Questions
Is Retatrutide legal to buy in the UK for research?+
Yes. Retatrutide is supplied as a research peptide for in-vitro laboratory use. It is not a licensed medicine in the UK and is not for human consumption.
Which is the most-studied of the three?+
Semaglutide has the longest research and clinical history. Tirzepatide is newer; Retatrutide is the newest and currently the most-requested for comparative receptor research.
Can I order all three from a UK supplier?+
Yes — Professor Peptide stocks Semaglutide, Tirzepatide and Retatrutide for UK research use, dispatched from the UK with CoA on request.